Nicholas C Borcherding

9PUBLICATIONS
73CO-AUTHORS
Molecular targetsSequence analysisInnate immunityCancer therapy (excl. chemotherapy and radiation therapy)Oncology and carcinogenesis not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 13, 2025
Somatic CRISPR tumorigenesis and multiomic analysis reveal a pentose phosphate pathway disruption vulnerability in MPNSTs.

Gavin R McGivney, Qierra R Brockman, Nicholas Borcherding

|Jun 27, 2025
scRepertoire 2: Enhanced and efficient toolkit for single-cell immune profiling.

Qile Yang, Ksenia R Safina, Kieu Diem Quynh Nguyen

|Jun 07, 2023
Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer.

Brett H Herzog, John M Baer, Nicholas Borcherding

|Feb 16, 2023
CD5 expression by dendritic cells directs T cell immunity and sustains immunotherapy responses.

Mingyu He, Kate Roussak, Feiyang Ma

|Sep 27, 2022
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint Blockade.

Varintra E Lander, Jad I Belle, Natalie L Kingston

|Sep 23, 2022
Correction: Pandey et al. ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer. Cancers 2019, 11, 718.

Gaurav Pandey, Nicholas Borcherding, Ryan Kolb

Pageof 2

Frequent Collaborators

2 joint publications

Graham D Hogg

2 joint publications

Liang-I Kang

2 joint publications

Brett L Knolhoff

2 joint publications

David G DeNardo